Chimeric Therapeutics Limited (CHMMF)
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.
Sector: Biotechnology
Industry: Biotechnology
Chimeric Therapeutics Limited
- Not computed yet: no FINRA short interest has been matched to this float.
- Not published: no settled short interest on record.
- Not stated: no basis-consistent volume to divide the settled position by.
Float 26.23M · FMP free float
The cost to borrow CHMMF shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- No fails on record for 16–31 Oct 2026.
No price or settlement history available to chart.
FINRA publishes no off-exchange short volume for this symbol.
FINRA's weekly alternative trading system (dark pool) volume for CHMMF: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.